Last year saw a dip in licensing deals across biopharma, though up-front payments held up and in some areas jumped considerably.
Thales, the final Brilinta outcome trial in Astrazeneca’s huge Parthenon programme, has hit – but the UK group’s vast investment in its blood thinner has yet to pay off.
A clutch of swift FDA decisions boosted average US drug approval times in 2019, helping biopharma to deliver another bumper crop of new medicines.
A look at the freshness of pharma's pipelines shows that Sanofi's new chief executive has his work cut out, while Lilly and Astrazeneca come up smelling of…
The device sector enjoyed a mid-year IPO bonanza, but after getting away the class of 2019 had a torrid time.
Biogen’s Alzheimer’s candidate and Fibrogen’s new anaemia pill top the list of the biggest commercial hopes that could reach the market in 2020.
The second half of 2019 saw half as many innovative medical devices approved as the first.
Private drug developers raised less last year than in 2018, but cash remains plentiful and mega rounds abound.
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.